{"id":145462,"date":"2022-09-02T01:24:04","date_gmt":"2022-09-02T06:24:04","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/09\/a-pharmaceutical-jack-of-all-trades-novo-ceo-touts-semaglutides-potential-in-nash-alzheimers-and-its-hot-start-in-obesity"},"modified":"2022-09-02T01:24:04","modified_gmt":"2022-09-02T06:24:04","slug":"a-pharmaceutical-jack-of-all-trades-novo-ceo-touts-semaglutides-potential-in-nash-alzheimers-and-its-hot-start-in-obesity","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/09\/a-pharmaceutical-jack-of-all-trades-novo-ceo-touts-semaglutides-potential-in-nash-alzheimers-and-its-hot-start-in-obesity","title":{"rendered":"A pharmaceutical jack of all trades? Novo CEO touts semaglutide\u2019s potential in NASH, Alzheimer\u2019s and its hot start in obesity"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/a-pharmaceutical-jack-of-all-trades-novo-ceo-touts-semaglutides-potential-in-nash-alzheimers-and-its-hot-start-in-obesity.jpg\"><\/a><\/p>\n<p>Novo Nordisk\u2019s recent growth renaissance has arrived thanks in no small part to semaglutide\u2014the GLP-1 molecule behind the company\u2019s leading marketed trio of Ozempic, Rybelsus and Wegovy.<\/p>\n<p>These days, much of the semaglutide hype surrounds Ozempic\u2019s domination in diabetes, plus Wegovy\u2019s potential to stir the slumbering giant that is the global obesity market. But even as the molecule\u2019s metabolic empire prospers, Novo Nordisk isn\u2019t letting its GLP-1 stay in its comfort zone. Novo is also pitting the drug against a pair of elusive targets: nonalcoholic steatohepatitis (NASH) and Alzheimer\u2019s disease.<\/p>\n<p>And while CEO Lars Fruergaard J\u00f8rgensen is quick to admit the company\u2019s ambitions in these new diseases are among Novo\u2019s \u201cmost risky\u201d R&amp;D endeavors, the payoff for patients could be \u201ctremendous,\u201d he said during a recent interview at Novo Nordisk\u2019s headquarters in Plainsboro, New Jersey.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk\u2019s recent growth renaissance has arrived thanks in no small part to semaglutide\u2014the GLP-1 molecule behind the company\u2019s leading marketed trio of Ozempic, Rybelsus and Wegovy. These days, much of the semaglutide hype surrounds Ozempic\u2019s domination in diabetes, plus Wegovy\u2019s potential to stir the slumbering giant that is the global obesity market. But even [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-145462","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/145462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=145462"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/145462\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=145462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=145462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=145462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}